Recent advances in prostate cancer treatment and drug discovery
E Nevedomskaya, SJ Baumgart… - International journal of …, 2018 - mdpi.com
Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …
Is cancer biology different in older patients?
Y Van Herck, A Feyaerts, S Alibhai… - The Lancet Healthy …, 2021 - thelancet.com
Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …
often diagnosed at a later stage and might receive less (intensive) treatment, which might …
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression
Prostate cancer shows remarkable clinical heterogeneity, which manifests in spatial and
clonal genomic diversity. By contrast, the transcriptomic heterogeneity of prostate tumours is …
clonal genomic diversity. By contrast, the transcriptomic heterogeneity of prostate tumours is …
The DNA methylation landscape of advanced prostate cancer
Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …
methylation landscape of metastatic cancer has never been defined. Through whole …
[PDF][PDF] Widespread and functional RNA circularization in localized prostate cancer
The cancer transcriptome is remarkably complex, including low-abundance transcripts,
many not polyadenylated. To fully characterize the transcriptome of localized prostate …
many not polyadenylated. To fully characterize the transcriptome of localized prostate …
Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial
Importance Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to
estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with …
estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with …
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a …
Background The majority of patients with metastatic castration-resistant prostate cancer
(mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by …
(mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by …
The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target
SG Zhao, J Lehrer, SL Chang, R Das… - JNCI: Journal of the …, 2019 - academic.oup.com
Background Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …
solid tumors. We sought to better understand the immune landscape in prostate cancer and …
Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences
W Rayford, AT Beksac, J Alger, M Alshalalfa… - Communications …, 2021 - nature.com
Racial disparities in prostate cancer have not been well characterized on a genomic level.
Here we show the results of a multi-institutional retrospective analysis of 1,152 patients (596 …
Here we show the results of a multi-institutional retrospective analysis of 1,152 patients (596 …